

Product datasheet for TL311143V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

NONO Human shRNA Lentiviral Particle (Locus ID 4841)

Product data:

Product Type: shRNA Lentiviral Particles

Product Name: NONO Human shRNA Lentiviral Particle (Locus ID 4841)

Locus ID: 4841

Synonyms: MRXS34; NMT55; NRB54; P54, P54NRB; PPP1R114

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: NONO - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 001145408, NM 001145409, NM 001145410, NM 007363, NM 007363.2, NM 007363.3,

NM 007363.4, NM 001145408.1, NM 001145409.1, NM 001145410.1, BC028299, BC012141, BC002364, BC003129, BC004113, BC010049, BC025280, BC025352, BC069616, BC069639,

NM 001145409.2, NM 001145408.2, NM 007363.5

UniProt ID: Q15233

Summary: This gene encodes an RNA-binding protein which plays various roles in the nucleus, including

transcriptional regulation and RNA splicing. A rearrangement between this gene and the transcription factor E3 gene has been observed in papillary renal cell carcinoma. Alternatively spliced transcript variants have been described. Pseudogenes exist on Chromosomes 2 and

16. [provided by RefSeq, Feb 2009]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.



NONO Human shRNA Lentiviral Particle (Locus ID 4841) - TL311143V

Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).